Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Perrigo: Vitamin sales rose 6% in fiscal Q1, outpacing gains in the overall market (2%) and store brands (5%), private labeler says, citing IRI data during Oct. 24 analysts call. "Led by bone health and women's health products, we continued to hold our own in a weak market," Exec VP & CFO Douglas Schrank asserts. Cough/cold/allergy sales gained 9% compared to overall market (up 1%), store brands (down 1%). Company expects negative impact in fiscal Q3 from launch of OTC loratadine (Schering-Plough's Claritin) by other companies, but positive turn in Q1 of fiscal 2004 with its own loratadine offering. Perrigo does not hold "first-to-file" status for any generic loratadine dosage form. First quarter sales fell 1.8% to $213.2 mil., due in part to difficult comparison to year-ago sell-in of famotidine. Net income jump of 52.9% to $20 mil. attributed to manufacturing efficiencies, improved pricing, vitamin settlement proceeds, 1Perrigo press release says...
Advertisement

Related Content

B&L exec sanctioned
B&L exec sanctioned
B&L exec sanctioned
Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy
Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy

Topics

Advertisement
UsernamePublicRestriction

Register

PS094709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel